GleamWall
中文EN

SRZN Surrozen, Inc./DE

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%

Returns

ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x

Leverage & solvency

Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$3.48M$10.65M
R&D expense$29.36M$21.13M
SG&A expense$16.20M$15.06M
Operating income-$42.09M-$25.54M
Pretax income-$242.03M-$63.56M
Income tax$0$0
Net income-$242.03M-$63.56M
EBITDA-$41.55M-$24.10M
EPS (basic)-32.37-21.67
EPS (diluted)-32.37-21.67
Weighted avg. shares (diluted)7,4782,933
Balance sheet
Cash & equivalents$89.25M$35.25M
Receivables$0$2.04M
Current assets$91.56M$38.93M
PP&E, net$433,000$562,000
Total assets$98.73M$48.47M
Current liabilities$9.93M$7.32M
Total liabilities$286.49M$69.85M
Shareholders' equity-$187.76M-$21.38M
Shares outstanding9.78M3.26M
Cash flow statement
Operating cash flow-$30.24M-$17.63M
Capital expenditure$128,000$26,000
Free cash flow-$30.37M-$17.65M
Investing cash flow-$128,000-$26,000
Financing cash flow$85.05M$16.18M
Depreciation & amortization$537,000$1.44M
Stock-based compensation$3.83M$4.11M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.